摘要:
The present invention is generally directed to Inhibitor of Apoptosis Proteins (“IAPs”), nucleic acid molecules encoding IAPs, viral vectors, recombinant baculoviruses comprising an IAP, transgenic plants comprising an IAP nucleic acid, and methods of assaying for compounds which bind to an IAP. In general, the IAP nucleic acids of the invention have 95% or higher identity to SEQ ID NO:1 and the IAP of the invention have 90% or higher identity to SEQ ID NO:3.
摘要翻译:本发明一般涉及凋亡蛋白(“IAP”)抑制剂,编码IAP的核酸分子,病毒载体,包含IAP的重组杆状病毒,包含IAP核酸的转基因植物,以及测定与 IAP。 通常,本发明的IAP核酸与SEQ ID NO:1具有95%或更高的同一性,并且本发明的IAP与SEQ ID NO:3具有90%或更高的同一性。
摘要:
The invention provides polypeptides comprising inhibitor of apoptosis protein (IAP) family members, such as BmIAP initially derived from Bombyx mori BmN cells, and nucleic acids encoding them, and methods for making and using these compositions, including their use for inhibiting apoptosis.
摘要:
The invention provides polypeptides comprising inhibitor of apoptosis protein (IAP) family members, such as BmIAP initially derived from Bombyx mori BmN cells, and nucleic acids encoding them, and methods for making and using these compositions, including their use for inhibiting apoptosis.
摘要:
The invention provides polypeptides comprising inhibitor of apoptosis protein (IAP) family members, such as BmIAP initially derived from Bombyx mori BmN cells, and nucleic acids encoding them, and methods for making and using these compositions, including their use for inhibiting apoptosis.
摘要:
A recombinant baculovirus is provided with a genetic coding sequence for the production of a foreign protein that is toxic to insects. Preferred are nuclear polyhedrosis viruses, with preferred embodiments having been constructed and expressed in insect cells: BmNPV.AaIT and AcNPV.AaIT. Both embodiments function in insect cells infected therewith so as to have the toxin AaIT (originating from the venom of the scorpion A. australis) secreted. A clone designated (pCIB4223), which contains the Bombyx mori signal sequence fused to the AaIT sequence, has been deposited with the American type culture collection and designated “ATCC 40906.”
摘要:
The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.
摘要:
Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.
摘要:
Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.
摘要:
The invention relates to methods, compositions, and uses of those compositions for making medicaments, for potentiating the beneficial effects of inhibitors of COX-1, COX-2, and 5-LOX, and reducing adverse effects, by also administering inhibitors of soluble epoxide hydrolase (“sEH”), with or without also administering one or more cis-epoxyeicosantrienoic acids. The invention further relates to the use of inhibitors of sEH as analgesics and to methods and compositions of epoxides of eicosapentaenoic acid and docosahexaenoic acid, optionally with an inhibitor of sEH, to reduce pain or inflammation or both.